INVASIVE INTERVENTIONS IN STRUCTURAL HEART DISEASES: COMPREHENSIVE TECHNIQUES

Invasive Interventions in Structural Heart Diseases-kapak

LONG-TERM OUTCOMES AND FOLLOW-UP AFTER CLOSURE ASD AND PFO

Mustafa Yaşan

Medical Park Samsun Hospital, Department of Cardiology, Samsun, Türkiye

Yaşan M. Long-Term Outcomes and Follow-Up After Closure ASD and PFO. In: Tanık VO, Özlek B, editors. Invasive Interventions in Structural Heart Diseases: Comprehensive Techniques. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.447-460.

ABSTRACT

In adults, percutaneous closure has become the preferred method for treating most secundum atrial septal defects (ASD) and patent foramen ovales (PFO). This approach has demonstrated safety and effectiveness, offering several benefits over surgical closure. These benefits include avoiding cardiopulmonary bypass and sternotomy, minimizing scarring, reducing hospital stays, and potentially lowering the risk of complications following the procedure. While the procedure itself and short-term outcomes have shown low rates of mortality and morbidity, the widespread use of ASD and PFO closure devices has revealed some rare and delayed complications. Device thrombosis and cardiac erosion are among the most severe late complications, while atrial arrhythmias are the most frequent. Other potential complications include nickel allergies, disturbances in cardiac conduction, damage to heart valves, and device-related endocarditis. Long-term complications, though infrequent, can be sudden and life-threatening. This chapter aims to discuss the types, frequencies, and outcomes of these rare but serious delayed complications associated with device closures.

Keywords: Closure ASD and PFO; Long-term Ourcomes and Follow-up

Referanslar

  1. Turner DR, Owada CY, Sang CJ Jr, Khan M, Lim DS. Closure of secundum atrial septal defects with the AMPLATZER septal occluder: a prospective, multicenter, post-approval study. Circ Cardiovasc Interv 2017;10:e004212. [Crossref]  [PubMed]  [PMC]
  2. McElhinney DB, Quartermain MD, Kenny D, Alboliras E, Amin Z. Relative risk factors for cardiac erosion following transcatheter closure of atrial septal defects: a case-control study. Circulation 2016;133:1738-1746. [Crossref]  [PubMed]
  3. Ho DY, Katcoff H, Griffis HM, Mercer-Rosa L, Fuller SM, Cohen MS. Left valvar morphology is associated with late regurgitation in atrioventricular canal defect. Ann Thorac Surg 2020;110:969-978. [Crossref]  [PubMed]  [PMC]
  4. John Sutton MG, Tajik AJ, McGoon DC. Atrial septal defect in patients ages 60 years or older: operative results and longterm postoperative follow-up. Circulation 1981;64:402-409. [Crossref]  [PubMed]
  5. Craig RJ, Selzer A. Natural history and prognosis of atrial septal defect. Circulation 1968;37:805-815. [Crossref]  [PubMed]
  6. Berger F, Vogel M, Kramer A, Alexi-Meskishvili V, Weng Y, Lange PE, et al. Incidence of atrial flutter/fibrillation in adults with atrial septal defect before and after surgery. Ann Thorac Surg 1999;68:75-78. [Crossref]  [PubMed]
  7. Houck CA, Lanters EAH, Heida A, Taverne Y, van de Woestijne PC, Knops P, et al. Distribution of conduction disorders in patients with congenital heart disease and right atrial volume overload. JACC Clin Electrophysiol 2020;6:537-548. [Crossref]  [PubMed]
  8. O'Neill L, Floyd CN, Sim I, Whitaker J, Mukherjee R, O'Hare D, et al. Percutaneous secundum atrial septal defect closure for the treatment of atrial arrhythmia in the adult: a meta-analysis. Int J Cardiol 2020;321:104-112. [Crossref]  [PubMed]
  9. Silversides CK, Haberer K, Siu SC, Webb GD, Benson LN, McLaughlin PR et al. Predictors of atrial arrhythmias after device closure of secundum type atrial septal defects in adults. Am J Cardiol 2008;101:683-687. [Crossref]  [PubMed]
  10. Gatzoulis MA, Freeman MA, Siu SC, Webb GD, Harris L. Atrial arrhythmia after surgical closure of atrial septal defects in adults. N Engl J Med 1999;340:839-846. [Crossref]  [PubMed]
  11. Humenberger M, Rosenhek R, Gabriel H, Rader F, Heger M, Klaar U, et al. Benefit of atrial septal defect closure in adults: impact of age. Eur Heart J 2011;32:553-560. [Crossref]  [PubMed]  [PMC]
  12. Karunanithi Z, Nyboe C, Hjortdal VE. Long-term risk of atrial fibrillation and stroke in patients with atrial septal defect diagnosed in childhood. Am J Cardiol 2017;119:461-465. [Crossref]  [PubMed]
  13. Nakagawa K, Akagi T, Nagase S, Takaya Y, Kijima Y, Toh N, et al. Efficacy of catheter ablation for paroxysmal atrial fibrillation in patients with atrial septal defect: a comparison with transcatheter closure alone. Europace 2019;21:1663-1669. [Crossref]  [PubMed]
  14. Santangeli P, Di Biase L, Burkhardt JD, Horton R, Sanchez J, Bailey S, et al. Transseptal access and atrial fibrillation ablation guided by intracardiac echocardiography in patients with atrial septal closure devices. Heart Rhythm 2011;8:1669-1675. [Crossref]  [PubMed]
  15. Lakkireddy D, Rangisetty U, Prasad S, Verma A, Biria M, Berenbom L, et al. Intracardiac echo-guided radiofrequency catheter ablation of atrial fibrillation in patients with atrial septal defect or patent foramen ovale repair: a feasibility, safety, and efficacy study. J Cardiovasc Electrophysiol 2008;19:1137-1142. [Crossref]  [PubMed]
  16. Houck CA, Evertz R, Teuwen CP, Roos-Hesselink JW, Duijnhouwer T, Bogers A, et al. Time course and interrelationship of dysrhythmias in patients with surgically repaired atrial septal defect. Heart Rhythm 2018;15:341-347. [Crossref]  [PubMed]
  17. Reddy BT, Patel JB, Powell DL, Michaels AD. Interatrial shunt closure devices in patients with nickel allergy. Catheter Cardiovasc Interv 2009;74:647-51. [Crossref]  [PubMed]
  18. S L Hill, C I Berul,H T Patel, J Rhodes, S E Supran,Q LCao, et al. Early ECG abnormalities associated with transcatheter closure of atrial septal defects using the Amplatzer septal occluder. J Interv Card Electrophysiol 2000;4:469-74. [PubMed]
  19. Nehgme RA, Huddleston AR, Cheatham JP. Progression to late complete atrioventricular block following Amplatzer device closure of atrial septal defect in a child. Pediatr Cardiol 2009;30:367-70. [Crossref]  [PubMed]
  20. Szkutnik M, Lenarczyk A, Kusa J, Białkowski J. Symptomatic tachy- and bradyarrhythmias after transcatheter closure of interatrial communications with Amplatzer devices. Cardiol J 2008;15:510-6. [Link]
  21. Dittrich S, Sigler M, Priessmann H. Late complete atrioventricular bloc after closure of an atrial septal defect with a gore septal occluder,GSO). Catheter Cardiovasc Interv 2016;87:945-50. [Crossref]  [PubMed]  [PMC]
  22. Engelfriet P, Meijboom F, Boersma E, Tijssen J, Mulder B. Repaired and open atrial septal defects type II in adulthood: an epidemiological study of a large European cohort. Int J Cardiol 2008;126:379-385. [Crossref]  [PubMed]
  23. Ho DY, Katcoff H, Griffis HM, Mercer-Rosa L, Fuller SM, Cohen MS. Left valvar morphology is associated with late regurgitation in atrioventricular canal defect. Ann Thorac Surg 2020;110:969-978. [Crossref]  [PubMed]  [PMC]
  24. Therrien J, Rambihar S, Newman B, Siminovitch K, Langleben D, Webb G et al. Eisenmenger syndrome and atrial septal defect: nature or nurture? Can J Cardiol 2006;22:1133-1136. [Crossref]  [PubMed]
  25. Vogel M, Berger F, Kramer A, Alexi-Meshkishvili V, Lange PE. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart 1999;82:30-33. [Crossref]  [PubMed]  [PMC]
  26. Lammers AE, Bauer LJ, Diller GP, Helm PC, Abdul-Khaliq H, Bauer UMM, et al. Pulmonary hypertension after shunt closure in patients with simple congenital heart defects. Int J Cardiol 2020;308:28-32. [Crossref]  [PubMed]
  27. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease-long-term follow-up and prediction of outcome after surgical correction. Circulation 1987;76:1037-1042. [Crossref]  [PubMed]
  28. Hoffmann A, Chockalingam P, Balint OH, Dadashev A, Dimopoulos K, Engel R, et al. Cerebrovascular accidents in adult patients with congenital heart disease. Heart 2010;96:1223-1226. [Crossref]  [PubMed]
  29. Nyboe C, Olsen MS, Nielsen-Kudsk JE, Hjortdal VE. Atrial fibrillation and stroke in adult patients with atrial septal defect and the long-term effect of closure. Heart 2015;101:706-711. [Crossref]  [PubMed]
  30. Abaci A, Unlu S, Alsancak Y, Kaya U, Sezenoz B. Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28,142 patients from 203 studies. Catheter Cardiovasc Interv 2013;82:1123-38. [Crossref]  [PubMed]
  31. Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004;43:302-9. [Crossref]  [PubMed]
  32. Delaney JW, Li JS, Rhodes JF. Major complications associated with transcatheter atrial septal occluder implantation: a review of the medical literature and the manufacturer and user facility device experience (MAUDE) database. Congenit Heart Dis 2007;2:256-64. [Crossref]  [PubMed]
  33. Sharafuddin MJ, Gu X, Titus JL, et al. Transvenous closure of secundum atrial septal defects: preliminary results with a new self-expanding nitinol prosthesis in a swine model. Circulation 1997;95:2162-8. [Crossref]  [PubMed]
  34. Thomsen AB, Schneider M, Baandrup U,E V Stenbøg,J M Hasenkam,J P Bagger, et al. Animal experimental implantation of an atrial septal defect occluder system. Heart 1998;80:606-11. [Crossref]  [PubMed]  [PMC]
  35. Zahn EM, Wilson N, Cutright W, Latson LA. Development and testing of the Helex septal occluder, a new expanded polytetrafluoroethylene atrial septal defect occlusion system. Circulation 2001;104:711-6. [Crossref]  [PubMed]
  36. Chessa M, Butera G, Frigiola A, Carminati M. Endothelialization of ASD devices for transcatheter closure: possibility or reality? Int J Cardiol 2004;97:563-4. [Crossref]  [PubMed]
  37. Chen F, Zhao X, Zheng X, Chen S, Xu R, Qin Y. Incomplete endothelialization and late dislocation after implantation of an Amplatzer septal occluder device. Circulation 2011;124:e188-9. [Crossref]
  38. Amin Z, Hijazi ZM, Bass JL, Chetham JP, Hellenbrand WE, Kleinman CS. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv 2004;63:496-502. [Crossref]  [PubMed]
  39. DiBardino DJ, McElhinney DB, Kaza AK, Mayer JE Jr. Analysis of the US Food and Drug Administration Manufacturer and User Facility Device Experience database for adverse events involving Amplatzer septal occluder devices and comparison with the Society of Thoracic Surgery congenital cardiac surgery database. J Thorac Cardiovasc Surg 2009;137:1334-41. [Crossref]  [PubMed]  [PMC]
  40. Amin Z. Echocardiographic predictors of cardiac erosion after amplatzer septal occluder placement. Catheter Cardiovasc Interv 2014;83:84-92. [Crossref]  [PubMed]
  41. Murphy JC, Walsh SJ, Spence MS. Late aortic perforation with an Atriasept device resulting in life-threatening tamponade. Catheter Cardiovasc Interv 2010;76:132-4. [Crossref]  [PubMed]
  42. Diab K, Kenny D, Hijazi ZM. Erosions, erosions, and erosions! Device closure of atrial septal defects: how safe is safe? Catheter Cardiovasc Interv 2012;80:168-74. [Crossref]  [PubMed]
  43. Fagan T, Dreher D, Cutright W, Jacobson J, Latson L. GORE HELEX Septal Occluder Working Group. Fracture of the GORE HELEX septal occluder: associated factors and clinical outcomes. Catheter Cardiovasc Interv 2009;73:941-8. [Crossref]  [PubMed]
  44. Hiraishi M, Tanaka H, Motoji Y, Sawa T, Tsuji T, Miyoshi T, et al. Impact of right ventricular geometry on mitral regurgitation after transcatheter closure of atrial septal defect. Int Heart J 2015;56:516-21. [Crossref]  [PubMed]
  45. Wilson NJ, Smith J, Prommete B, O'Donnell C, Gentles T, Ruygrok P. Transcatheter closure of secundum atrial septal defects with the Amplatzer septal occluder in adults and children-follow-up closure rates, degree of mitral regurgitation and evolution of arrhythmias. Heart Lung Circ 2008;17:318-24. [Crossref]  [PubMed]
  46. Takaya Y, Kijima Y, Akagi T, Nakagawa K, Oe H, Taniguchi M et al. Fate of mitral regurgitation after transcatheter closure of atrial septal defect in adults. Am J Cardiol 2015;116:458-62. [Crossref]  [PubMed]
  47. Schoen SP, Boscheri A, Lange SA, Braub MU,Fuhrmann J, Strasser SE. Incidence of aortic valve regurgitation and outcome after percutaneous closure of atrial septal defects and patent foramen ovale. Heart 2008;94:844-7. [Crossref]  [PubMed]
  48. Sadiq M, Kazmi T, Rehman AU,Latif F, Hyder N, Qureshi SA. Device closure of atrial septal defect: Medium-term outcome with special reference to complications. Cardiol Young 2012;22:71-8. [Crossref]  [PubMed]
  49. Loar RW, Johnson JN, Cabalka AK, Cetta F, Hagler DJ, Eidem BW, et al. Effect of percutaneous atrial septal defect and patent foramen ovale device closure on degree of aortic regurgitation. Catheter Cardiovasc Interv 2013;81:1234-7. [Crossref]  [PubMed]
  50. Fang F, Wang J, Yip GW, Lam YY. Predictors of mid-term functional tricuspid regurgitation after device closure of atrial septal defect in adults: impact of pre-operative tricuspid valve remodeling. Int J Cardiol 2015;187:447-52. [Crossref]  [PubMed]
  51. Rodes-Cabau J, Mineau S, Marrero A, Houde C, Mackey A,Cote J et al. Incidence, timing, and predictive factors of new-onset migraine headache attack after transcatheter closure of atrial septal defect or patent foramen ovale. Am J Cardiol 2008;101:688-92. [Crossref]  [PubMed]
  52. Wertman B, Azarbal B, Riedl M, Tobis J. Adverse events associated with nickel allergy in patients undergoing percutaneous atrial septal defect or patent foramen ovale closure. J Am Coll Cardiol 2006;47:1226-7. [Crossref]  [PubMed]
  53. Sharifi M, Burks J. Efficacy of clopidogrel in the treatment of post-ASD closure migraines. Catheter Cardiovasc Interv 2004;63:255. [Crossref]  [PubMed]
  54. Wei SH, Fan PC, Kuo PH, Chiou LC, Wang JK. Calcitonin gene-related peptide and size of the atrial septal defect in new-onset migraine after transcatheter closure: results of a preliminary study. Headache 2012;52: 985-92. [Crossref]  [PubMed]
  55. Rodes-Cabau J, Horlick E, Ibrahim R, Cheema AN, Nadeem N, Osten M et al. Effect of clopidogrel and aspirin vs aspirin alone on migraine headaches after transcatheter atrial septal defect closure: the CANOA Randomized Clinical Trial. JAMA 2015;314:2147-54. [Crossref]  [PubMed]
  56. Verma DR, Khan MF, Tandar A, Rajasekaran NS, Neuharth R, Patel AN et al. Nickel elution properties of contemporary interatrial shunt closure devices. J Invasive Cardiol 2015;27:99-104. [PubMed]
  57. Reddy BT, Patel JB, Powell DL, Michaels AD. Interatrial shunt closure devices in patients with nickel allergy. Catheter Cardiovasc Interv 2009;74:647-51. [Crossref]  [PubMed]
  58. Slesnick TC, Nugent AW, Fraser CD Jr, Cannon BC. Incomplete endothelialization and late development of acute bacterial endocarditis after implantation of an Amplatzer septal occluder device. Circulation 2008;117:e326-7. [Crossref]  [PubMed]
  59. Zahr F, Katz WE, Toyoda Y, Anderson WD. Late bacterial endocarditis of an Amplatzer atrial septal defect occluder device. Am J Cardiol 2010;105:279-80. [Crossref]  [PubMed]
  60. Aruni B, Sharifian A, Eryazici P, Herrera CJ. Late bacterial endocarditis of an Amplatzer atrial septal device. Indian Heart J 2013;65:450-1. [Crossref]  [PubMed]  [PMC]
  61. Kim DJ, Shim CY, You SC, Lee SH, Hong GR. Late bacterial endocarditis and abscess formation after implantation of an Amplatzer septal occluder device. Circulation 2015;131:e536-8. [Crossref]  [PMC]
  62. Thibodeau-Jarry N, Ibrahim R, Ducharme A, Sia YT. Late infection of an atrial septal defect closure device: a possible complication. Can J Cardiol 2015;31:1204.e9-11. [Crossref]  [PubMed]
  63. Habib G, Lancellotti P, Antunes MJ, Casalta JP, Zotti FD, Dulgheru R et al. ESC Guidelines for the management of infective endocarditis The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015;36:3075-128. [Crossref]  [PubMed]
  64. Zakaria Jalal, Sebastien Hascoet, Alban-Elouen Baruteau. Long-term Complications After Transcatheter Atrial Septal Defect Closure: A Review of the Medical Literature. Canadian Journal of Cardiology 2016;32(11):1315.e11e1315. [Crossref]  [PubMed]
  65. Martin SS, Shapiro eP, Mukherjee M. Atrial septal defects- clinical manifestations, echo assessment, and intervention. Clin Med Insights Cardiol. 2015;8(Suppl 1):93-8. [Crossref]  [PubMed]  [PMC]
  66. Baharestani B, Rezaei S, Jalili Shahdashti F, Omrani G, Heidarali M. Experiences in surgical closure of atrial septal defect with anterior minithoracotomy approach. J Cardiovasc Thorac Res. 2014;6:181-4. [Crossref]  [PubMed]  [PMC]
  67. Ford MA, Reeder GS, Lennon RJ, Robert D Brown, George W Petty, Allison K Cabalka, et al. Percutaneous device closure of patent foramen ovale in patients with presumed cryptogenic stroke or transient ischemic attack: the Mayo clinic experience. JACC Cardiovasc Interv. 2009;2:404-11. [Crossref]  [PubMed]
  68. Wilson W, Taubert KA, Gewitz M, Peter B Lockhart, Larry M Baddour, Matthew Levison, et al. American Dental Association. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116:1736-54. [Link]
  69. van riel aC, Blok IM, zwinderman aH, Wajon eM, Sadee aS, Bakker-de Boo M, et al. lifetime risk of Pulmonary Hypertension for all Patients after Shunt Closure. J am Coll Cardiol. 2015;66(9):1084-6. [Crossref]  [PubMed]
  70. Niwa K. Adult Congenital Heart Disease with Pregnancy. Korean Circ J. 2018;48(4):251-76. [Crossref]  [PubMed]  [PMC]
  71. Francesco Santini, Mohammed Morjan, Francesco Onorati, Giorgio Morando, Giuseppe Faggian, Alessandro Mazzuccol. Life-threatening isometric-exertion related cardiac perforation 5 years after Amplatzer atrial septal defect closure: should isometric activity be limited in septal occluder holders? Ann Thorac Surg 2012;93:671. [Crossref]  [PubMed]
  72. Yared K, Baggish AL, Solis J, Durst R, Passeri JJ, Palacios IF, Picard MH. Echocardiographic assessment of percutaneous patent foramen ovale and atrial septal defect closure complications. Circ Cardiovasc Imaging 2009;2:141-149. [Crossref]  [PubMed]
  73. Amedro P, Soulatges C, Fraisse A. Infective endocarditis after device closure of atrial septal defects: Case report and review of the literature. Catheter Cardiovasc Interv 2017;89:324-334. [Crossref]  [PubMed]
  74. Krantz SB, Lawton JS. Subacute endocarditis of an atrial septal closure device in a patient with a patent foramen ovale. Ann Thorac Surg 2014;98:1821-1823. [Crossref]  [PubMed]
  75. Thornhill MH, Jones S, Prendergast B, Baddour LM, Chambers JB, Lockhart PB, Dayer MJ. Quantifying infective endocarditis risk in patients with predisposing cardiac conditions. Eur Heart J 2018;39:586-595. [Crossref]  [PubMed]  [PMC]
  76. Collado FMS, Poulin MF, Murphy JJ, Jneid H, Kavinsky CJ. Patent foramen ovale closure for stroke prevention and other disorders. J Am Heart Assoc 2018;7 007146. [Crossref]  [PubMed]  [PMC]
  77. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL. RESPECT Investigators. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017;377:1022-1032. [Crossref]  [PubMed]
  78. Mookadam F, Jiamsripong P, Goel R, Warsame TA, Emani UR, Khandheria BK. Critical appraisal on the utility of echocardiography in the management of acute pulmonary embolism. Cardiol Rev 2010;18:29-37. [Crossref]  [PubMed]
  79. Vitarelli A, Sardella G, Roma AD, Capotosto L, De Curtis G, D'Orazio S, et al. Assessment of right ventricular function by three-dimensional echocardiography and myocardial strain imaging in adult atrial septal defect before and after percutaneous closure. Int J Cardiovasc Imag 2012;28:1905-1916. [Crossref]  [PubMed]
  80. Greutmann M, Greutmann-Yantiri M, Kretschmar O, Senn O, Roffi M, Jenni R, Luescher TF, Eberli FR. Percutaneous PFO closure with Amplatzer PFO occluder: Predictors of residual shunts at 6 months follow-up. Congenit Heart Dis 2009;4:252-257. [Crossref]  [PubMed]
  81. Shah AH, Osten M, Benson L, Alnasser S, Bach Y, Vishwanath R, et al. Incidence and outcomes of positive bubble contrast study results after transcatheter closure of a patent foramen ovale. JACC Cardiovasc Interv 2018;11:1095-1104. [Crossref]  [PubMed]
  82. Wintzer-Wehekind J, Alperi A, Houde C, C^ot e JM, Asmarats L, C^ot e M, Rod es-Cabau J. Long-term follow-up after closure of patent foramen ovale in patients with cryptogenic embolism. J Am Coll Cardiol 2019;73:278-287. [Crossref]  [PubMed]
  83. Yamashita E, Oshima S. Transesophageal echocardiography for the detection of patent foramen ovale (Authors' Reply). J Am Soc Echocardiogr. 2017;30:934-935. [Crossref]  [PubMed]
  84. Susuri N, Obeid S, Ulmi M, Siontis GCM, Wahl A, Windecker S, Nietlispach F, Meier B, Praz F. Second transcatheterclosure for residual shunt following percutaneous closure ofpatent foramen ovale. EuroIntervention 2017;13:858-866. [Crossref]  [PubMed]
  85. Abushora MY, Bhatia N, Alnabki Z, Shenoy M, Alshaher M,Stoddard MF. Intrapulmonary shunt is a potentially unrecognized cause of ischemic stroke and transient ischemic attack. J Am Soc Echocardiogr. 2013;26:683-690. [Crossref]  [PubMed]
  86. Sinha RS, Hussain Z, Bhatia N, Stoddard MF. Risk of recurrent neurologic stroke or transient ischemic attack in patients with cryptogenic stroke and intrapulmonary shunt. Echocardiography 2016;33:276-280. [Crossref]  [PubMed]